These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21864240)

  • 1. Sphingolipid modulation: a strategy for cancer therapy.
    Delgado A; Fabrias G; Bedia C; Casas J; Abad JL
    Anticancer Agents Med Chem; 2012 May; 12(4):285-302. PubMed ID: 21864240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.
    Canals D; Perry DM; Jenkins RW; Hannun YA
    Br J Pharmacol; 2011 Jun; 163(4):694-712. PubMed ID: 21615386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel chemotherapeutic drugs in sphingolipid cancer research.
    Canals D; Hannun YA
    Handb Exp Pharmacol; 2013; (215):211-38. PubMed ID: 23579458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicinal chemistry aspects of drug targets in sphingolipid metabolism.
    Nussbaumer P
    ChemMedChem; 2008 Apr; 3(4):543-51. PubMed ID: 18061920
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibitors of sphingolipid metabolism enzymes.
    Delgado A; Casas J; Llebaria A; Abad JL; Fabrias G
    Biochim Biophys Acta; 2006 Dec; 1758(12):1957-77. PubMed ID: 17049336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of ceramide 1-O-functionalization as a promising approach for cancer therapy.
    Ballereau S; Levade T; Genisson Y; Andrieu-Abadie N
    Anticancer Agents Med Chem; 2012 May; 12(4):316-28. PubMed ID: 21554198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis.
    Quinville BM; Deschenes NM; Ryckman AE; Walia JS
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of ceramide analogs as potential anticancer agents.
    Liu J; Beckman BS; Foroozesh M
    Future Med Chem; 2013 Aug; 5(12):1405-21. PubMed ID: 23919551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of sphingolipid metabolism in cancer.
    Ryland LK; Fox TE; Liu X; Loughran TP; Kester M
    Cancer Biol Ther; 2011 Jan; 11(2):138-49. PubMed ID: 21209555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.
    Gatt S; Dagan A
    Chem Phys Lipids; 2012 May; 165(4):462-74. PubMed ID: 22387097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingolipid metabolizing enzymes as novel therapeutic targets.
    Billich A; Baumruker T
    Subcell Biochem; 2008; 49():487-522. PubMed ID: 18751924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingolipids and response to chemotherapy.
    Dimanche-Boitrel MT; Rebillard A
    Handb Exp Pharmacol; 2013; (216):73-91. PubMed ID: 23563652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical tools to investigate sphingolipid metabolism and functions.
    Delgado A; Casas J; Llebaria A; Abad JL; Fabriás G
    ChemMedChem; 2007 May; 2(5):580-606. PubMed ID: 17252619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology.
    Merrill AH; Schmelz EM; Dillehay DL; Spiegel S; Shayman JA; Schroeder JJ; Riley RT; Voss KA; Wang E
    Toxicol Appl Pharmacol; 1997 Jan; 142(1):208-25. PubMed ID: 9007051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.
    Shaw J; Costa-Pinheiro P; Patterson L; Drews K; Spiegel S; Kester M
    Adv Cancer Res; 2018; 140():327-366. PubMed ID: 30060815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural products as platforms for the design of sphingolipid-related anticancer agents.
    Delgado A; Fabriàs G; Casas J; Abad JL
    Adv Cancer Res; 2013; 117():237-81. PubMed ID: 23290782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of sphingosine-1-phosphate metabolism (sphingosine kinases and sphingosine-1-phosphate lyase).
    Sanllehí P; Abad JL; Casas J; Delgado A
    Chem Phys Lipids; 2016 May; 197():69-81. PubMed ID: 26200919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of Ceramidases.
    Saied EM; Arenz C
    Chem Phys Lipids; 2016 May; 197():60-8. PubMed ID: 26220616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingolipid homeostasis in the web of metabolic routes.
    Aguilera-Romero A; Gehin C; Riezman H
    Biochim Biophys Acta; 2014 May; 1841(5):647-56. PubMed ID: 24184514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceramidases in hematological malignancies: senseless or neglected target?
    Fabrias G; Bedia C; Casas J; Abad JL; Delgado A
    Anticancer Agents Med Chem; 2011 Nov; 11(9):830-43. PubMed ID: 21707488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.